ArticleNature2024
In vivo interaction screening reveals liver-derived constraints to metastasis.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Article
- HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Context-Dependent Roles of the Plexin-B Family Across Neurological, Oncological, Immune and Cardiovascular Disorders: Mechanisms and Therapeutic Implications.Life (Basel, Switzerland) · 2026Review
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- A DPHV-liver module recapitulates AML infiltration and chemotherapy-induced hepatotoxicity with translational utility.Science advances · 2026Article
- Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT.Nature biotechnology · 2026Article
- Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity.Nature cancer · 2026Review
- Frazzled/DCC directs spatial progenitor integration ensuring steady-state intestinal turnover.Nature communications · 2026Article
- Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis.Signal transduction and targeted therapy · 2026Article
- Navigating the Tumor Microenvironment in Colorectal Liver Metastasis: Barriers to Therapy and Emerging Opportunities.Oncology research · 2026Review
- Context-Dependent Dual Roles of the Plexin-B Family in Cancer Progression: Mechanisms and Therapeutic Implications.Cancer management and research · 2026Review
- Tumor Microenvironment-Responsive Nanoparticles for Pancreatic Cancer Imaging and Treatment.International journal of nanomedicine · 2026Review
- Mechanistic insights into hepatic metastasis of pancreatic cancer: molecular perspectives.Translational gastroenterology and hepatology · 2026Review
- SLC2A3 Expression is Differentially Associated with Postoperative Recurrence, Complications, and Liver Metastasis in Colorectal Cancer.Cancer management and research · 2026Article
- Plexin A2 Knockdown Enhances Apoptosis in Chemotherapy Treated Melanoma Cells.Oncology research · 2026Article
- Review
- The immune microenvironment of colorectal cancer.Nature reviews. Cancer · 2025Review
- The liver talks back: NPY orchestrates attraction of cancer cells and CHK2-dependent clonogenicity in the metastatic niche.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Costanza BorrelliDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0002-8732-773X
Morgan RobertsDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0009-0003-8029-807X
Davide ElettoDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0002-2650-1968
Marie-Didiée HussherrDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Hassan FazilatyDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-9387-0413
Tomas ValentaDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3043-1835
Atefeh LafziDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Jonas A KretzDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0003-4023-4103
Elena Guido VinzoniDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0009-0003-7163-1360
Andromachi KarakatsaniDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Srivathsan AdivarahanDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Ardian MannhartDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Shoichiro KimuraDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Ab MeijsDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0002-9205-6292
Farah Baccouche MhamediDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Ilhan E AcarDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0002-2078-9905
Kristina HandlerDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Xenia FichtDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0002-4534-8225
Randall J PlattDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0002-2914-7052
Salvatore PiscuoglioIRCCS Humanitas Research Hospital, Milan, Italy.
Andreas E MoorDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. andreas.moor@bsse.ethz.ch.ORCID 0000-0001-8715-8449
Funding
Swiss Federal Institute of Technology Zurich
Abstract
It is estimated that only 0.02% of disseminated tumour cells are able to seed overt metastases
Indexed as
CRISPR-Cas SystemsHepatocytesLiverLiver NeoplasmsNeoplasm MetastasisNerve Tissue ProteinsAnimalsCell Line, TumorColorectal NeoplasmsDisease Models, AnimalDNA Transposable ElementsFemaleFluorescenceHumansKruppel-Like Factor 4MaleDNA Transposable ElementsKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4Nerve Tissue ProteinsPLXNB2 protein, humanPlxnb2 protein, mouseSemaphorins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.